Systemic immune-inflammation index predicts survival in gastric cancer: a systematic review and meta-analysis
Abstract
ObjectiveTo comprehensively assess the association of pretreatment systemic immune-inflammation index (SII) with the prognosis of gastric cancer patients.MethodsPubMed, Web of Science, Embase, and the Cochrane Library were searched to select studies exploring the association of SII with the overall survival (OS), progression-free survival (PFS) or recurrence-free survival (RFS) of gastric cancer. We pooled the hazard ratios (HRs) with 95% confidence intervals (CIs) using a random-effects model. Robustness was assessed by sensitivity analyses, and publication bias was evaluated using funnel plots and Egger’s regression test.ResultsA total of 61 studies involving 66 cohorts and 31,608 patients were included in this meta-analysis, with most studies adopting a retrospective design and only one prospective study enrolled. Elevated pretreatment SII was significantly correlated with inferior OS (HR = 1.48, 95% CI: 1.36–1.62), PFS (HR = 1.43, 95% CI: 1.30–1.58), and RFS (HR = 1.38, 95% CI: 1.09–1.76). Subgroup analyses demonstrated that the magnitude of the prognostic association varied across treatment modalities and geographic regions.ConclusionIn conclusion, we found that elevated pretreatment SII is a potential biomarker for adverse prognosis in gastric cancer patients. However, since nearly all included studies were retrospective and only one was a prospective study, our findings support the prognostic value of SII, but prospective validation is required before routine clinical implementation.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/, identifier CRD420261321880.
Related
- Integrating overall survival and health-related quality of life to prioritize first-line systemic therapies for unresectable advanced gastric cancer: a network meta-analysis
- Effects of Bioactive Compound Supplementation on Insulin Resistance and Systemic Inflammation in Overweight and Obese Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
- Preoperative Systemic Immune-Inflammation Index and Clinical Outcomes After Coronary Artery Bypass Grafting: A Systematic Review and Meta-analysis
- Molecular Profiles, Treatment-Associated Survival, and Prognosis in Early-Onset Versus Late-Onset Gastric Cancer: A Systematic Review and Meta-Analysis
- Associations between pretreatment systemic immune-inflammation index and tumor-specific prognosis in breast and gynecological cancers: an updated systematic review, meta-analysis, and certainty-of-evidence assessment
BibTeX
@article{yu2026systemic,
title = {{Systemic immune-inflammation index predicts survival in gastric cancer: a systematic review and meta-analysis}},
author = {Ziyi Yu and Xue Liu and Guoliang Hu and Lingling Zhao and Tingting Liang},
journal = {Frontiers in Oncology},
year = {2026},
month = oct,
doi = {10.3389/fonc.2026.1953559},
url = {https://www.frontiersin.org/articles/10.3389/fonc.2026.1953559},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Systemic immune-inflammation index predicts survival in gastric cancer: a systematic review and meta-analysis
AU - Ziyi Yu
AU - Xue Liu
AU - Guoliang Hu
AU - Lingling Zhao
AU - Tingting Liang
PY - 2026
DA - 2026/10/30
JO - Frontiers in Oncology
DO - 10.3389/fonc.2026.1953559
UR - https://www.frontiersin.org/articles/10.3389/fonc.2026.1953559
AB - ObjectiveTo comprehensively assess the association of pretreatment systemic immune-inflammation index (SII) with the prognosis of gastric cancer patients.MethodsPubMed, Web of Science, Embase, and the Cochrane Library were searched to select studies exploring the association of SII with the overall survival (OS), progression-free survival (PFS) or recurrence-free survival (RFS) of gastric cancer. We pooled the hazard ratios (HRs) with 95% confidence intervals (CIs) using a random-effects model. Robustness was assessed by sensitivity analyses, and publication bias was evaluated using funnel plots and Egger’s regression test.ResultsA total of 61 studies involving 66 cohorts and 31,608 patients were included in this meta-analysis, with most studies adopting a retrospective design and only one prospective study enrolled. Elevated pretreatment SII was significantly correlated with inferior OS (HR = 1.48, 95% CI: 1.36–1.62), PFS (HR = 1.43, 95% CI: 1.30–1.58), and RFS (HR = 1.38, 95% CI: 1.09–1.76). Subgroup analyses demonstrated that the magnitude of the prognostic association varied across treatment modalities and geographic regions.ConclusionIn conclusion, we found that elevated pretreatment SII is a potential biomarker for adverse prognosis in gastric cancer patients. However, since nearly all included studies were retrospective and only one was a prospective study, our findings support the prognostic value of SII, but prospective validation is required before routine clinical implementation.Systematic review registrationhttps://www.crd.york.ac.uk/PROSPERO/, identifier CRD420261321880.
SN - 2234-943X
ER -